Analyses Adjusting for Selective Crossover Show Improved Overall Survival with Decitabine Compared with Treatment Choice in DACO-016 Phase III Trial
Nov 1, 2013, 00:00 AM
10.1016/j.jval.2013.08.322
https://www.valueinhealthjournal.com/article/S1098-3015(13)02227-4/fulltext
Section Title :
Disease-Specific Studies
Section Order :
308
First Page :
A378
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02227-4&doi=10.1016/j.jval.2013.08.322